Overview

* Acurx Q3 net loss narrows to $2 mln, with EPS at -$1.23

* R&D expenses decreased to $0.4 mln due to lower manufacturing and consulting costs

* Company completed 1-for-20 reverse stock split, regaining Nasdaq compliance

Result Drivers

* REVERSE STOCK SPLIT - Co completed a 1-for-20 reverse stock split, regaining Nasdaq compliance

* R&D EXPENSES - R&D expenses decreased due to lower manufacturing and consulting costs

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS -$1.23

Q3 Net -$2 mln

Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Acurx Pharmaceuticals Inc ( ACXP ) is $30.50, about 81.7% above its November 11 closing price of $5.58

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)